芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

orion corporation - methotrexate - injektioneste, liuos, esitäytetty ruisku - 25 mg/ml - metotreksaatti

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

sandoz a/s sandoz a/s - tadalafilum - tabletti, kalvopäällysteinen - 2.5 mg - tadalafiili

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

sandoz a/s - tadalafil - tabletti, kalvopäällysteinen - 5 mg - tadalafiili

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

sandoz a/s - tadalafil - tabletti, kalvopäällysteinen - 10 mg - tadalafiili

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

sandoz a/s - tadalafil - tabletti, kalvopäällysteinen - 20 mg - tadalafiili

欧盟 - 芬兰文 - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - huumeisiin liittyviä sivuvaikutuksia ja haittavaikutuksia - kaikki muut terapeuttiset tuotteet - aikuisilla potilailla, joilla on suora hyytymistekijä xa: n (fxa) estäjä (apixaban tai rivaroksabaani), kun käänteinen antikoagulaatio tarvitaan, koska henkeä uhkaava tai hallitsematon verenvuoto.

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

laboratoire aguettant - suxamethonium chloride anhydrous - injektioneste, liuos, esitäytetty ruisku - 10 mg/ml - suksametoni

芬兰 - 芬兰文 - Fimea (Suomen lääkevirasto)

aop orphan pharmaceuticals gmbh - tadalafil - tabletti, kalvopäällysteinen - 20 mg - tadalafiili

欧盟 - 芬兰文 - EMA (European Medicines Agency)

astrazeneca ab - anifrolumab - lupus erythematosus, systemaattinen - immunosuppressantit - saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (sle), despite standard therapy.